tbuckley/cabot-search huggingface dataset:
Hybrid mRNA Nano Vaccine Potentiates Antigenic Peptide Presentation and Dendritic Cell Maturation for Effective Cancer Vaccine Therapy and Enhances Response to Immune Checkpoint Blockade (Adv. Healthcare Mater. 32/2023)
Authors: Lu Shi, Jingxing Yang, Ying Nie, Yizhou Huang, Hongchen Gu
Journal: Advanced Healthcare Materials (2023)

Nano Vaccines In article 2301261 by Hongchen Gu and co-workers, a hybrid mRNA-based nano vaccine is reported with the potential to promote the peptide presentation of intratumoral dendritic cells and macrophages. With the anti-PD-1 antibody, the nano vaccine arouses robust tumor suppression in murine models with large tumor burdens (initial volume > 300 mm3). The mRNA vaccine represents a transformable platform and augments response to ICB.
Glycoprotein Injectable Hydrogels Promote Accelerated Bone Regeneration through Angiogenesis and Innervation (Adv. Healthcare Mater. 32/2023)
Authors: Debyashreeta Barik, Sharmistha Shyamal, Kapilash Das, Sarita Jena, Mamoni Dash
Journal: Advanced Healthcare Materials (2023)

Bone Regeneration In article 2301959 by Mamoni Dash and co-workers, the modification of mucin by conjugating PNIPAM and the formation of thermoreversible hydrogels with protein (collagen and mucin), is presented.
Magnetic Delivery of Antigen‐Loaded Magnetic Liposomes for Active Lymph Node Targeting and Enhanced Anti‐Tumor Immunity (Adv. Healthcare Mater. 32/2023)
Authors: Jingyi Sheng, Yang Liu, He Ding, Linyuan Wu, Lan Liu, Guangxiang Si, Yan Shen, Fang Yang, Ning Gu
Journal: Advanced Healthcare Materials (2023)

Vaccine Delivery In article 2301232, Jingyi Sheng, Fang Yang, Ning Gu, and co-workers introduce a magnetic-responsive cancer vaccine, employing antigen-loaded magnetic liposomes (Ag-MLs), for active lymph node targeting. These liposomes, containing mouse melanoma lysate, iron oxide nanoparticles, and CpG adjuvant, display enhanced accumulation in lymph nodes when magnetically guided and demonstrate significant enhancement in anti-tumor immunity in a mouse model. This approach provides potential new avenues for developing effective tumor vaccines.
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)
Authors: Jonathan I. Silverberg, Bruce Strober, Brian Feinstein, Jinhua Xu, Emma Guttman-Yassky, Eric L. Simpson, Pauline Li, Malinda Longphre, Jing Song, Jiawang Guo, Jang Yun, Belinda Williams, Wubin Pan, Selwyn Ho, Raúl Collazo, Zheng Wei
Journal: Journal of Allergy and Clinical Immunology (2023)
IL-13 and IL-13–induced periostin levels are specifically decreased in patients following endoscopic sinus surgery for chronic rhinosinusitis
Authors: Regan Harmon, Alexander L Schneider, Junqin Bai, Samuel D Racette, Abhita T Reddy, Julia H Huang, David S Lehmann, Caroline P E Price, Samuel Rodeghiero, Aditi Agarwal, Jacob G Eide, Siyuan Dong, David B Conley, Kevin C Welch, Robert C Kern, Stephanie Shintani-Smith, Anju T Peters, Atsushi Kato, Whitney W Stevens, Lutfiyya N Muhammad, Robert P Schleimer, Bruce K Tan
Journal: Journal of Allergy and Clinical Immunology (2023)
Retuning Mitochondrial Apoptosis/Mitophagy Balance via SIRT3‐Energized and Microenvironment‐Modulated Hydrogel Microspheres to Impede Osteoarthritis (Adv. Healthcare Mater. 32/2023)
Authors: Xiaowei Xia, Yang Liu, Yingjie Lu, Junlin Liu, Yaoge Deng, Yubin Wu, Mingzhuang Hou, Fan He, Huilin Yang, Yong Xu, Yijian Zhang, Xuesong Zhu
Journal: Advanced Healthcare Materials (2023)

Responsive Microspheres In article 2302475 by Huilin Yang, Yong Xu, Yijian Zhang, Xuesong Zhu, and co-workers, a microenvironment responsive hydrogel microsphere is developed to rebalance BCL2/BAX-cytochrome c (mtApoptosis) and PINK1/Parkin-LC3B-P62 (mitophagy) through activation of the mitochondrial guardian SIRT3. Restoring mitochondrial homeostasis proves effective in rescuing extracellular matrix disintegration and restraining articular cartilage degeneration, thereby providing a novel organelle-oriented strategy for treating osteoarthritis.
Self‐Assembled Virus‐Like Particle Vaccines via Fluorophilic Interactions Enable Infection Mimicry and Immune Protection (Adv. Healthcare Mater. 32/2023)
Authors: Yinhe Xia, Kai Liu, Fei Wang, Zhou Xu, Yuesheng Wang, Rongling Zong, Yemin Xu, Ping Li, Bin Deng, Maolei Xu, Gang Chen
Journal: Advanced Healthcare Materials (2023)

Virus-Like Particle Vaccines ln article 2301647, Bin Deng, Maolei Xu, Gang Chen, and co-workers develop a methodology to generate virus-like particles (VLPs) based on fluorophilic interactions. The VLPs mimic the viral infection processes, achieve improved immune potency, and exhibit comprehensive protection against infection.
Direct Mapping of Cytomechanical Homeostasis Destruction in Osteoarthritis Based on Silicon Nanopillar Array (Adv. Healthcare Mater. 32/2023)
Authors: Dengjie Yu, Qingbin Nie, Jiangtao Xue, Ruizeng Luo, Shiwang Xie, Shengyu Chao, Engui Wang, Linlin Xu, Yizhu Shan, Zhuo Liu, Yusheng Li, Zhou Li
Journal: Advanced Healthcare Materials (2023)

Mechanopharmacology In article number 2301126 by Zhuo Liu, Yusheng Li, Zhou Li, and co-workers, a silicon nanopillar array (Si-NP) with high spatial resolution and promising mechanical property is fabricated to directly reflect the cytomechanical homeostasis destruction in osteoarthritis (OA) by measuring the cell traction force, which provides a deeper understanding of the progression of OA. Meanwhile, the Si-NP also shows the potential in disease diagnosis and drug screening from a cytomechanical standpoint.
Thymic stromal lymphopoietin induces IL-4/IL-13 from T cells to promote sebum secretion and adipose loss
Authors: Ruth Choa, Jordan C. Harris, EnJun Yang, Yuichi Yokoyama, Mariko Okumura, MinJu Kim, Jerrick To, Meng Lou, Amanda Nelson, Taku Kambayashi
Journal: Journal of Allergy and Clinical Immunology (2023)
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain
Authors: Lekha Mikkilineni, Danielle A. Natrakul, Norris Lam, Elisabet E. Manasanch, Jennifer Mann, Katherine A. Weissler, Nathan Wong, Jennifer N. Brudno, Stephanie L. Goff, James C. Yang, Micaela Ganaden, Rashmika Patel, Zhili Zheng, Jared J. Gartner, Kathryn R. Martin, Hao-Wei Wang, Constance M. Yuan, Tyler Lowe, Irina Maric, Lipei Shao, Ping Jin, David F. Stroncek, Steven L. Highfill, Steven A. Rosenberg, James N. Kochenderfer
Journal: Molecular Therapy (2023)
Melanoma and microbiota: Current understanding and future directions
Authors: Bertrand Routy, Tanisha Jackson, Laura Mählmann, Christina K. Baumgartner, Martin Blaser, Allyson Byrd, Nathalie Corvaia, Kasey Couts, Diwakar Davar, Lisa Derosa, Howard C. Hang, Geke Hospers, Morten Isaksen, Guido Kroemer, Florent Malard, Kathy D. McCoy, Marlies Meisel, Sumanta Pal, Ze’ev Ronai, Eran Segal, Gregory D. Sepich-Poore, Fyza Shaikh, Randy F. Sweis, Giorgio Trinchieri, Marcel van den Brink, Rinse K. Weersma, Katrine Whiteson, Liping Zhao, Jennifer McQuade, Hassane Zarour, Laurence Zitvogel
Journal: Cancer Cell (2023)

Over the last decade, the composition of the gut microbiota has been found to correlate with the outcomes of cancer patients treated with immunotherapy. Accumulating evidence points to the various mechanisms by which intestinal bacteria act on distal tumors and how to harness this complex ecosystem to circumvent primary resistance to immune checkpoint inhibitors. Here, we review the state of the microbiota field in the context of melanoma, the recent breakthroughs in defining microbial modes of action, and how to modulate the microbiota to enhance response to cancer immunotherapy. The host-microbe interaction may be deciphered by the use of "omics" technologies, and will guide patient stratification and the development of microbiota-centered interventions. Efforts needed to advance the field and current gaps of knowledge are also discussed.
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer
Authors: Gianluca Mucciolo, Joaquín Araos Henríquez, Muntadher Jihad, Sara Pinto Teles, Judhell S. Manansala, Wenlong Li, Sally Ashworth, Eloise G. Lloyd, Priscilla S.W. Cheng, Weike Luo, Akanksha Anand, Ashley Sawle, Anna Piskorz, Giulia Biffi
Journal: Cancer Cell (2023)

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Cancer-associated fibroblasts (CAFs) are recognized potential therapeutic targets, but poor understanding of these heterogeneous cell populations has limited the development of effective treatment strategies. We previously identified transforming growth factor beta (TGF-β) as a main driver of myofibroblastic CAFs (myCAFs). Here, we show that epidermal growth factor receptor/Erb-B2 receptor (EGFR/ERBB2) signaling is induced by TGF-β in myCAFs through an autocrine process mediated by amphiregulin. Inhibition of this EGFR/ERBB2-signaling network in PDAC organoid-derived cultures and mouse models differentially impacts distinct CAF subtypes, providing insights into mechanisms underpinning their heterogeneity. Remarkably, EGFR-activated myCAFs promote PDAC metastasis in mice, unmasking functional significance in myCAF heterogeneity. Finally, analyses of other cancer datasets suggest that these processes might operate in other malignancies. These data provide functional relevance to myCAF heterogeneity and identify a candidate target for preventing tumor invasion in PDAC.
Genome-wide classification of epigenetic activity reveals regions of enriched heritability in immune-related traits
Authors: Miriam Stricker, Weijiao Zhang, Wei-Yi Cheng, Steven Gazal, Calliope Dendrou, Satu Nahkuri, Pier Francesco Palamara
Journal: Cell Genomics (2023)

Epigenetics underpins the regulation of genes known to play a key role in the adaptive and innate immune system (AIIS). We developed a method, EpiNN, that leverages epigenetic data to detect AIIS-relevant genomic regions and used it to detect 2,765 putative AIIS loci. Experimental validation of one of these loci, DNMT1, provided evidence for a novel AIIS-specific transcription start site. We built a genome-wide AIIS annotation and used linkage disequilibrium (LD) score regression to test whether it predicts regional heritability using association statistics for 176 traits. We detected significant heritability effects (average |τ∗|=1.65) for 20 out of 26 immune-relevant traits. In a meta-analysis, immune-relevant traits and diseases were 4.45× more enriched for heritability than other traits. The EpiNN annotation was also depleted of trans-ancestry genetic correlation, indicating ancestry-specific effects. These results underscore the effectiveness of leveraging supervised learning algorithms and epigenetic data to detect loci implicated in specific classes of traits and diseases.
Circulating NK cells establish tissue residency upon acute infection of skin and mediate accelerated effector responses to secondary infection
Authors: Tommaso Torcellan, Christin Friedrich, Rémi Doucet-Ladevèze, Thomas Ossner, Virgínia Visaconill Solé, Sofie Riedmann, Milas Ugur, Fabian Imdahl, Stephan P. Rosshart, Sebastian J. Arnold, Mercedes Gomez de Agüero, Nicola Gagliani, Richard A. Flavell, Simone Backes, Wolfgang Kastenmüller, Georg Gasteiger
Journal: Immunity (2023)

Natural killer (NK) cells are present in the circulation and can also be found residing in tissues, and these populations exhibit distinct developmental requirements and are thought to differ in terms of ontogeny. Here, we investigate whether circulating conventional NK (cNK) cells can develop into long-lived tissue-resident NK (trNK) cells following acute infections. We found that viral and bacterial infections of the skin triggered the recruitment of cNK cells and their differentiation into Tcf1
Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation
Authors: Vidhi Chandra, Le Li, Olivereen Le Roux, Yu Zhang, Rian M. Howell, Dhwani N. Rupani, Seyda Baydogan, Haiyan D. Miller, Erick Riquelme, Joseph Petrosino, Michael P. Kim, Krishna P.L. Bhat, James R. White, Jay K. Kolls, Yuliya Pylayeva-Gupta, Florencia McAllister
Journal: Cancer Cell (2023)
Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy
Authors: Elias Bou Farhat, Elio Adib, Melissa Daou, Elizabeth P. Henske, Abdul Rafeh Naqash, Ursula Matulonis, Kimmie Ng, David J. Kwiatkowski, Lynette M. Sholl, Amin H. Nassar
Journal: Cancer Cell (2023)
The role of mitochondrial dynamics in disease
Authors: Yujuan Wang, Xinyan Dai, Hui Li, Huiling Jiang, Junfu Zhou, Shiying Zhang, Jiacheng Guo, Lidu Shen, Huantao Yang, Jie Lin, Hengxiu Yan
Journal: MedComm (2023)

Mitochondria are multifaceted and dynamic organelles regulating various important cellular processes from signal transduction to determining cell fate. As dynamic properties of mitochondria, fusion and fission accompanied with mitophagy, undergo constant changes in number and morphology to sustain mitochondrial homeostasis in response to cell context changes. Thus, the dysregulation of mitochondrial dynamics and mitophagy is unsurprisingly related with various diseases, but the unclear underlying mechanism hinders their clinical application. In this review, we summarize the recent developments in the molecular mechanism of mitochondrial dynamics and mitophagy, particularly the different roles of key components in mitochondrial dynamics in different context. We also summarize the roles of mitochondrial dynamics and target treatment in diseases related to the cardiovascular system, nervous system, respiratory system, and tumor cell metabolism demanding high-energy. In these diseases, it is common that excessive mitochondrial fission is dominant and accompanied by impaired fusion and mitophagy. But there have been many conflicting findings about them recently, which are specifically highlighted in this view. We look forward that these findings will help broaden our understanding of the roles of the mitochondrial dynamics in diseases and will be beneficial to the discovery of novel selective therapeutic targets.
Risk factors for prolonged grief symptoms: A systematic review and meta-analysis
Authors: C. Buur, R. Zachariae, K.B. Komischke-Konnerup, M.M. Marello, L.H. Schierff, M. O'Connor
Journal: Clinical Psychology Review (2023)

The diagnosis Prolonged Grief Disorder (PGD) has recently been included in ICD-11 and DSM-5-TR. To identify individuals who need help coping with grief, knowledge is needed about who is at risk of developing PGD. We, therefore, conducted a comprehensive systematic review and meta-analysis of the available literature on risk factors for prolonged grief symptoms (PGS). Based on a literature search in PsycInfo, PubMed, Web of Science, and CINAHL, we included the most frequently investigated risk factors in a meta-analysis. The effect size correlation was used as the standardized measure of the strength of the association between the risk factor and PGS. Based on 120 studies of 61.580 participants published between 1989 and 2023, 19 risk factors were included in the meta-analysis. For the adjusted associations, the strongest associations with PGS were pre-loss grief symptoms (ESr = 0.39, 95%CI[0.24–0.53]) and depression (ESr = 0.30, 95%CI[0.13–0.44]). Small, but statistically significant associations were observed for unexpected death, violent/unnatural death, low educational level, low income, female gender, anxious attachment style, and death of a child or partner. An updated overview of risk factors for PGS is presented, including their predictive strength. The results offer knowledge that can aid prevention and early identification of people at risk of PGD.
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial
Authors: James Chih-Hsin Yang, Baohui Han, Emmanuel De La Mora Jiménez, Jong-Seok Lee, Piotr Koralewski, Nuri Karadurmus, Shunichi Sugawara, Lorenzo Livi, Naveen S. Basappa, Xavier Quantin, Julia Dudnik, Diego Moran Ortiz, Tarek Mekhail, Chinyere E. Okpara, Corina Dutcus, Zachary Zimmer, Ayman Samkari, Niyati Bhagwati, Tibor Csőszi
Journal: Journal of Thoracic Oncology (2023)

Introduction Lenvatinib plus pembrolizumab demonstrated antitumor activity and acceptable safety in previously treated metastatic NSCLC. We evaluated first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in metastatic NSCLC in the LEAP-007 study (NCT03829332/NCT04676412). Methods Patients with previously untreated stage IV NSCLC with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥1% without targetable EGFR/ROS1/ALK aberrations were randomized 1:1 to lenvatinib 20 mg or placebo once daily; all patients received pembrolizumab 200 mg every 3 weeks for ≤35 cycles. Primary endpoints were progression-free survival (RECIST version 1.1) and overall survival (OS). We report results from a prespecified nonbinding futility analysis of OS performed at the fourth independent data and safety monitoring committee (DMC) review (futility bound: 1-sided P<0.4960). Results 623 patients were randomized. At median follow-up of 15.9 months, median (95% CI) OS was 14.1 (11.4‒19.0) months in the lenvatinib plus pembrolizumab group versus 16.4 (12.6‒20.6) months in the placebo plus pembrolizumab group (HR, 1.10 [95% CI, 0.87‒1.39]; P=0.79744 [futility criterion met]). Median (95% CI) progression-free survival was 6.6 (6.1‒8.2) versus 4.2 (4.1‒6.2) months, respectively (HR, 0.78 [95% CI, 0.64‒0.95]). Grade 3‒5 treatment-related adverse events (AEs) occurred in 57.9% of patients (179/309) versus 24.4% (76/312). Per DMC recommendation, the study was unblinded and lenvatinib and placebo were discontinued. Conclusions Lenvatinib plus pembrolizumab did not have a favorable benefit‒risk profile versus placebo plus pembrolizumab. Pembrolizumab monotherapy remains an approved treatment option in many regions for first-line metastatic NSCLC with PD-L1 TPS ≥1% without EGFR/ALK alterations.
Hepatitis B virus (HBV) screening, linkage and retention-in-care in inclusion health populations: Evaluation of an outreach screening programme in London
Authors: Emily Martyn, Sive O’Regan, Philippa Harris, Mark Leonard, Martha Veitch, Binta Sultan, Philippa C. Matthews, Indrajit Ghosh, Alistair Story, Julian Surey
Journal: Journal of Infection (2023)

ObjectivesWe evaluate a hepatitis B virus (HBV) screening programme, delivered by a specialist pan-London multidisciplinary outreach team, to understand population characteristics and care cascade among people who experience extreme social exclusion (Inclusion Health (IH) groups).MethodsPoint-of-care HBV screening was performed in temporary accommodation for people experiencing homelessness (PEH) and people seeking asylum (initial accommodation centres, IACs) via a mobile unit staffed by peers with lived experience, nurses, and doctors. We analysed demographics and HBV characteristics of adults screened between May 2020 and January 2022. We ascertained linkage-to-care (LTC), retention-in-care (RIC) and loss-to-follow-up (LTFU). People LTFU were contacted by peers to re-engage in care.Results2473 people were screened: 809 in IACs, 1664 in other temporary accommodation. Overall hepatitis B surface antigen (HBsAg) prevalence was 1.7% (43/2473), highest in IACs (3.5%, 28/809). LTC within 3 months was 56% (24/43) and RIC, 87% (26/30). LTC was higher when referred to a local IH-specialist hepatitis service, compared to other services (77%, 17/22 vs 33%, 7/21; p=0.006). LTFU was 30% (13/43), reduced to 21% (9/43) after intervention by peers.ConclusionOur findings support outreach screening among IH populations and peer-supported linkage to IH-specialist hepatitis services. We recommend increased HBV testing and HBV-specific IH specialist services.
Carbon nanotubes targeted to the tumor microenvironment inhibit metastasis in a preclinical model of melanoma
Authors: Lorena García-Hevia, Rym Soltani, Jesús González, Olivier Chaloin, Cécilia Ménard-Moyon, Alberto Bianco, Mónica L. Fanarraga
Journal: Bioactive Materials (2023)

Despite notable progress in cancer therapy, metastatic diseases continue to be the primary cause of cancer-related mortality. Multi-walled carbon nanotubes (MWCNTs) can enter tissues and cells and interfere with the dynamics of the cytoskeletal nanofilaments biomimetically. This endows them with intrinsic anti-tumoral effects comparable to those of microtubule-binding chemotherapies such as Taxol®. In this study, our focus was on exploring the potential of oxidized MWCNTs in selectively targeting the vascular endothelial growth factor receptor (VEGFR). Our objective was to evaluate their effectiveness in inhibiting metastatic growth by inducing anti-proliferative, anti-migratory, and cytotoxic effects on both cancer and tumor microenvironment cells. Our findings demonstrated a significant reduction of over 80 % in malignant melanoma lung metastases and a substantial enhancement in overall animal welfare following intravenous administration of the targeted biodegradable MWCNTs. Furthermore, the combination of these nanomaterials with the conventional chemotherapy agent Taxol® yielded a remarkable 90 % increase in the antimetastatic effect. These results highlight the promising potential of this combined therapeutic approach against metastatic disease and are of paramount importance as metastasis is responsible for nearly 60,000 deaths each year.
Construction of tissue-engineered vascular grafts with enhanced patency by integrating heparin, cell-adhesive peptide, and carbon monoxide nanogenerators into acellular blood vessels
Authors: Yonghong Fan, Juan Pei, Yinhua Qin, Huifang Du, Xiaohang Qu, Wenya Li, Boyue Huang, Ju Tan, Yong Liu, Gang Li, Ming Ke, Youqian Xu, Chuhong Zhu
Journal: Bioactive Materials (2023)

Small-diameter tissue-engineered vascular grafts (sdTEVGs) have garnered significant attention as a potential treatment modality for vascular bypass grafting and replacement therapy. However, the intimal hyperplasia and thrombosis are two major complications that impair graft patency during transplantation. To address this issue, we fabricated the covalent-organic framework (COF)-based carbon monoxide (CO) nanogenerator-and co-immobilized with LXW-7 peptide and heparin to establish a multifunctional surface on TEVGs constructed from acellular blood vessels for preventing thrombosis and stenosis. The cell-adhesive peptide LXW-7 could capture endothelial-forming cells (EFCs) to promote endothelialization, while the antithrombotic molecule heparin prevented thrombus formation. The reactive oxygen species (ROS)-triggered CO release suppressed the adhesion and activation of macrophages, leading to the reduction of ROS and inflammatory factors. As a result, the endothelial-to-mesenchymal transition (EndMT) triggered by inflammation was restricted, facilitating the maintenance of the homeostasis of the neo-endothelium and preventing pathological remodeling in TEVGs. When transplanted in vivo, these vascular grafts exhibited negligible intimal hyperplasia and remained patent for 3 months. This achievement provided a novel approach for constructing antithrombotic and anti-hyperplastic TEVGs.
Microgel-based carriers enhance skeletal stem cell reprogramming towards immunomodulatory phenotype in osteoarthritic therapy
Authors: Pei-Lin Li, Da-Fu Chen, Xiao-Tong Li, Rui-Cong Hao, Zhi-Dong Zhao, Zhi-Ling Li, Bo-Feng Yin, Jie Tang, Yu-Wen Luo, Chu-Tse Wu, Jing-Jun Nie, Heng Zhu
Journal: Bioactive Materials (2023)

Skeletal stem cells (SSC) have gained attentions as candidates for the treatment of osteoarthritis due to their osteochondrogenic capacity. However, the immunomodulatory properties of SSC, especially under delivery operations, have been largely ignored. In the study, we found that Pdpn